OliX Pharmaceuticals Presents Potential Utility of GalNAc-asiRNA Platform at OPT Congress

SUWON, South Korea–()–OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that Behfar Ardehali, Ph.D., Senior Scientist of the Company, presented at the 7th Annual OPT Congress Oligonucleotide & Precision Therapeutics. The OPT Congress is being held both in-person and virtually March 15-16, 2022. At the congress, Dr. Ardehali discussed the potential utility of GalNAc-asiRNA platform for treatment of liver diseases and presented the Company’s latest advancements in liver programs, including Nonalcoholic steatohepatitis (NASH) and HBV.

Details for the presentation are below:

Presentation: Development of a GalNAc-asiRNA Platform for Treatment of Liver Disorders

Date & Time: Tuesday, March 15, 2022 at 11:00 AM EDT

Location: Revere Hotel Boston Common, USA

Event Link: https://www.optcongress.com

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating the expression of disease-causing genes based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology. Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Learn more: https://www.olixpharma.com/eng

Source link

The content is by Business Wire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.

Comments are closed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy